REVISTA

Ziconotide para el tratamiento del dolor crónico severo

Valoración Valoración: 4 Estrellas

Descripción: La ziconotida, un subtipo de bloqueante de los canales de calcio, puede ser una alternativa para el tratamiento del dolor crónico severo refractario.

TITULO FUENTE ORIGINAL:

Ziconotide for treatment of severe chronic pain

AUTORES:

Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G

REVISTA ABREV.:

Lancet

AÑO:

2010

REFERENCIA:

1;375(9725):1569-77

DOI:

10.1016/S0140-6736(10)60354-6

RESUMEN ORIGINAL:

Pharmacological management of severe chronic pain is difficult to achieve with currently available analgesic drugs, and remains a large unmet therapeutic need. The synthetic peptide ziconotide has been approved by the US Food and Drug Administration and the European Medicines Agency for intrathecal treatment of patients with severe chronic pain that is refractory to other treatment modalities.... + Leer más

Pharmacological management of severe chronic pain is difficult to achieve with currently available analgesic drugs, and remains a large unmet therapeutic need. The synthetic peptide ziconotide has been approved by the US Food and Drug Administration and the European Medicines Agency for intrathecal treatment of patients with severe chronic pain that is refractory to other treatment modalities. Ziconotide is the first member in the new drug class of selective N-type voltage-sensitive calcium-channel blockers. The ziconotide-induced blockade of N-type calcium channels in the spinal cord inhibits release of pain-relevant neurotransmitters from central terminals of primary afferent neurons. By this mechanism, ziconotide can effectively reduce pain. However, ziconotide has a narrow therapeutic window because of substantial CNS side-effects, and thus treatment with ziconotide is appropriate for only a small subset of patients with severe chronic pain. We provide an overview of the benefits and limitations of intrathecal ziconotide treatment and review potential future developments in this new drug class.

- Leer menos

ENLACES DE INTERÉS

Web del contenido: http://www.thelancet.com/journals/lancet/arti[...]